Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and
characterized in 1999. It is required for the generation of all monomeric forms of amyloid-β …

Intense multidisciplinary research has provided detailed knowledge of the molecular
pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new …

Recent efforts have revealed that numerous protein-coding messenger RNAs have natural
antisense transcript partners, most of which seem to be noncoding RNAs. Here we identify a …

Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in
onset and progression of the condition would significantly reduce the global burden of the …

Alzheimer's disease is a progressive, clinically heterogeneous, and particularly complex
neurodegenerative disease characterized by a decline in cognition. Over the last two …

BACKGROUND: In the earliest clinical stages of Alzheimer's disease (AD) when symptoms
are mild, clinical diagnosis can be difficult. AD pathology most likely precedes symptoms …

Subjects with mild cognitive impairment (MCI) have an increased risk to develop Alzheimer's
disease (AD). Voxel-based MRI studies have demonstrated that widely distributed cortical …

The protease β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is required
for the production of the amyloid-β (Aβ) peptide, which is central to the pathogenesis of …

Beta amyloid, Aβ 1–42, originally named as Amyloid A4 protein, is one of the most
investigated peptides in neuroscience and has attracted substantial interest since its …